[Tenofovir and entecavir for chronic hepatitis B infection treatment: a single-center experience]

Fabio Tarsetti, Giuseppe Tarantino, Piergiorgio Mosca, Emidio Scarpellini, Giammarco Fava

DOI: https://doi.org/10.7175/cmi.v9i4.1202


BACKGROUND AND AIM: The current treatment of chronic hepatitis B infection (CHBV) has achieved several step-ups thanks to the introduction of the new-generation nucleos(t)ide analogs. Entecavir and tenofovir have shown a high genetic resistance barrier and a low rate of side effects. In literature, there are a few studies comparing entecavir and tenofovir in the treatment of CHBV. Thus, we describe the results of our experience in managing CHBV patients with tenofovir vs. entecavir.

MATERIALS AND METHODS: We have retrospectively evaluated, from 2007 to date, 20 CHBV patients treated with entecavir and tenofovir. All the patients underwent basal and periodical clinical follow-up, blood tests, virological tests, Fibroscan® test or liver biopsy and also upper abdominal ultrasound examination. Study endpoints were: viral replication inhibition, viral antigens seroconversion and transaminases normalization. Drug-associated side effects were also registered.

RESULTS: After 12 weeks of therapy, entecavir and tenofovir lead to HBV-DNA negativization in 44% and 62% of patients, respectively. A case of viral seroconversion for HBeAg and HBsAg was evident in entecavir group, while no cases were registered in tenofovir group. After 12 weeks, 11% of entecavir treated patients and 37% of tenofovir treated patients showed normalization of transaminases.

DISCUSSION: Tenofovir seems to exert a better viral replication inhibition (though not statistically significant) and to show transaminases improvement in comparison with entecavir, which, in turn, results more effective in HBeAg/HBsAg seroconversion. Both drugs have a high safety profile in terms of side effects.

[Article in Italian]


HBV; Entecavir; Tenofovir; Seroconversion

Full Text



  • McMahon BJ. Epidemiology and natural history of hepatitis B. Semin Liver Dis 2005; 25: 3-8; http://dx.doi.org/10.1055/s-2005-915644
  • Fattovich G, Stroffolini T, Zagni I, et al. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004; 127: 35-50; http://dx.doi.org/10.1053/j.gastro.2004.09.014
  • European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-85; http://dx.doi.org/10.1016/j.jhep.2012.02.010
  • Tang CM, Yau TO, Yu J. Management of chronic hepatitis B infection: current treatment guidelines, challenges, and new developments. World J Gastroenterol 2014; 20: 6262-78; http://dx.doi.org/10.3748/wjg.v20.i20.6262
  • Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-2; http://dx.doi.org/10.1002/hep.23190
  • Carosi G, Rizzetto M, Alberti A, et al. Treatment of chronic hepatitis B: update of the recommendations from the 2007 Italian Workshop. Dig Liver Dis 2011; 43: 259-65; http://dx.doi.org/10.1016/j.dld.2010.10.014
  • Liaw YF, Kao JH, Piratvisuth T, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 2012; 6: 531-61; http://dx.doi.org/10.1007/s12072-012-9386-z; http://dx.doi.org/10.1007/s12072-012-9365-4
  • Pérez-Cameo C, Pons M, Esteban R. New therapeutic perspectives in HBV: when to stop NAs. Liver Int 2014; 34: 146-53; http://dx.doi.org/10.1111/liv.12398
  • Ke W, Liu L, Zhang C, et al. Comparison of efficacy and safety of tenofovir and entecavir in chronic hepatitis B virus infection: a systematic review and meta-analysis. PLoS One 2014; 9:e98865; http://dx.doi.org/10.1371/journal.pone.0098865
  • Batirel A, Guclu E, Arslan F, et al. Comparable efficacy of tenofovir versus entecavir and predictors of response in treatment-naïve patients with chronic hepatitis B: a multicenter real-life study. Int J Infect Dis 2014; 28: 153-9; http://dx.doi.org/10.1016/j.ijid.2014.09.004
  • Huang M, Jie Y, Shi H, et al. Comparison of the efficacy of tenofovir disoproxil fumarate and entecavir for initial treatment of patient with chronic hepatitis B in China. Int J Clin Exp Med 2015; 8: 666-73
  • Woo G, Tomlinson G, Nishikawa Y, et al. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology 2010; 139: 1218-29; http://dx.doi.org/10.1053/j.gastro.2010.06.042
  • Wilder J, Patel K. The clinical utility of FibroScan® as a noninvasive diagnostic test for liver disease. Med Devices (Auckl) 2014; 7: 107-14; http://dx.doi.org/10.2147/MDER.S46943
  • Lok AS, Trinh H, Carosi G, et al. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B. Gastroenterology 2012; 143: 619-628.e1; http://dx.doi.org/10.1053/j.gastro.2012.05.037


Abstract: 1251 views
HTML: 1259 views
PDF: 272 views


  • There are currently no refbacks.